FGF21 gene therapy(Kriya Therapeutics)

N/A

Report date: 2023/11/03 16:58:10

Base Information

Drug NameFGF21 gene therapy(Kriya Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionFibroblast growth factor 21 modulators
TargetsFibroblast growth factor 21
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKriya Therapeutics IncTramontane Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKriya Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A